Commercial Launch CorneaGen recently announced the commercial availability of Corneal Tissue Addition for Keratoplasty (CTAK), signaling an active product roll-out and potential demand generation opportunities with ophthalmology clinics performing keratoplasty and contouring procedures.

Innovation Pipeline A track record of new tissue processing technologies and surgical devices, including EndoSerter-PL, indicates ongoing product innovation suitable for upsell conversations with surgeons and hospital systems seeking advanced cornea care solutions.

Strategic Growth As the world’s leading eye bank with multiple U.S. locations and local partnerships, CorneaGen presents a broad geographic footprint for expanding tissue sourcing, service contracts, and co-marketing initiatives with eye care networks.

Leadership Momentum Recent leadership appointment with Bernie Iliakis as president reflects organizational focus and stability, presenting a favorable context for enterprise sales discussions around long-term partnerships and strategic initiatives.

Financial and Market Position With substantial Series B funding and revenue in the mid-range (tens of millions), CorneaGen demonstrates financial capacity to invest in expanded services, reimbursement advocacy programs, and payer-related solutions that can be bundled with tissue and device offerings.